An Adrenal Mass Found by Accident: Functional vs Malignant Workup

The reassuring part first. The large majority of these masses are benign nonfunctioning adenomas that will never cause trouble. The workup exists to catch the small minority that behave differently, either by pumping out a hormone or by looking like a cancer, before they are waved through as nothing.

The two questions that drive everything

An adrenal mass found by accident is judged on two axes, and they are independent. The first: is it functional, meaning is it secreting a hormone it should not. The second: is it malignant, meaning does it look like a cancer. A mass can be one, both, or neither, and the answers point to different next steps.

This is why a single scan is never the end of it. Imaging speaks to malignancy risk. It says almost nothing about whether the gland is quietly flooding the body with cortisol or adrenaline. That takes blood and urine. A good workup runs both tracks at once instead of chasing the scariest word on the report and forgetting the rest.

Is it functional: the hormone workup

Even a mass causing no obvious symptoms gets a hormone screen, because autonomous secretion is often silent for years while it drives up blood pressure, blood sugar, and bone loss. Per the AACE/AAES guideline, the standard screen has two parts run on nearly everyone.

Cortisol comes first, tested with a 1 mg overnight dexamethasone suppression test: you take dexamethasone at bedtime and a morning cortisol is drawn. In a normal gland, cortisol suppresses. A morning value that fails to drop below roughly 1.8 micrograms per deciliter flags autonomous cortisol secretion and usually earns a confirmatory test. Pheochromocytoma is the second, screened with plasma fractionated metanephrines or 24-hour urine metanephrines, because a mass that secretes adrenaline can be dangerous if handled or operated on unprepared. The third track is conditional: aldosterone and renin, measured as the aldosterone-to-renin ratio, but only in people who are hypertensive or hypokalemic, since primary aldosteronism is the aldosterone-driven cause of that pairing. If you want the mechanics of these panels, how adrenal and cortisol testing actually works walks through them, and a good blood test ai analyzer can hold the results side by side, but the interpretation is what matters, and a value that fails to suppress is not the same as a value that is flat wrong.

Is it malignant: what the imaging says

Malignancy risk rests mostly on two imaging features: size and density. On the size axis, the NIH consensus grouped masses by adrenocortical carcinoma risk, roughly 2 percent under 4 cm, about 6 percent between 4 and 6 cm, and around 25 percent over 6 cm. That is why 4 cm is the number that gets everyone's attention, though size alone never decides it.

Density does the heavier lifting. On an unenhanced CT, attenuation of 10 Hounsfield units or less is the most widely accepted threshold for a benign lipid-rich adenoma, with a sensitivity reported around 96 to 100 percent per AJR imaging literature, because benign adenomas are fat-rich and cancers are not. When a mass is denser than that and cannot be called benign outright, a contrast washout study helps: adenomas flush contrast out quickly, and an absolute washout of at least 60 percent, or a relative washout of at least 40 percent, points to a benign adenoma. Any careful ai ct scan analysis has to weigh size, density, and washout together rather than reacting to one number in isolation.

When it is nothing, and when it is not

Most incidentalomas that are small, under 10 Hounsfield units on unenhanced CT, and hormonally silent are benign adenomas that need little more than confirmation. The ones that pull attention are the opposite profile: larger than 4 cm, dense or inhomogeneous on imaging, or biochemically active. Those get closer follow-up, and sometimes a surgical referral, because that combination is where adrenocortical carcinoma, which is rare overall at under 2 percent of incidentalomas, actually concentrates. If the report itself is what has you worried, what to do about an incidental finding covers the general path. The point of the workup is not to panic over every shadow. It is to make sure the one mass that is different does not get filed next to the ninety-nine that are not.

How Healz reads an adrenal incidentaloma

The trap with an incidentaloma is fragmentation. The CT lives with radiology, the hormone panels come back on different days from the lab, and no single visit puts size, density, and biochemistry on one page. Healz is equipped with Frontier AI, so it holds the mass measurement, the Hounsfield density, the washout numbers, and the cortisol, metanephrine, and aldosterone-renin results together and reads them as one case. That is the combination that decides the answer, and it is the combination that usually never sits in front of one set of eyes.

Healz is equipped with root-cause technology, so it does not stop at the word on the report. It cross-checks your case against more than a million rare cases and asks the questions a fast read skips: was cortisol actually confirmed, was the aldosterone-renin ratio even ordered given the blood pressure, does the density match the size. Healz has memory that keeps every prior scan and lab, so when a follow-up CT lands months later it compares the mass to its own baseline and flags real growth instead of noise. Everything sits in one chat, not scattered across ten apps and three portals. If you are weighing a second opinion, this is the case being read whole rather than one number at a time. When you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.